Silver Book Fact
A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took alendronate. The study followed about 1,200 women with low bone mass for over a year.
Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass Treated With 6-monthly Denosumab or Weekly Alendronate. http://www.rheumatology.org/press/2008/2008_press_14.asp. Published 2008